|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
EASE OF MOVEMENT
Trading: HOLD @ $0.037
Signal Strength: MEDIUM
Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.
The Ease of Movement (EOM) is a technical momentum indicator that is used to illustrate the relationship between the rate of an assets price change and its volume. This indicator attempts to identify the amount of volume required to move prices. Generally a value greater than zero is an indication that the stock is being accumulated (bought) and negative values are used to signal increased selling pressure. A high positive value appears when prices move upward on low volume. Strong negative numbers indicate that price is moving downward on low volume.
Calculation: Ease of Movement (EOM):
1) Distance Moved = ((H + L)/2 - (Prior H + Prior L)/2);
2) Box Ratio = ((V/100 000 000)/(H - L));
3) 1-Period EMV = ((H + L)/2 - (Prior H + Prior L)/2) / ((V/100 000 000)/(H - L));
4) 14-Period Ease of Movement = 14-Period simple moving average of 1-period EMV
PROFILE: Bionomics (BNO.AX)
Stock Exchange: ASX
Ticker Codes: | BNO.AX | ASX:BNO |
Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments. The company's product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trial for the treatment of generalized anxiety disorder, as well as is in the initiation of a Phase II clinical trial in patients with post-traumatic stress disorder; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that targets cancer stem cells; and BNC105, a vascular disrupting agent for the treatment of cancer, as well as disrupts the blood vessels that nourish tumors in cancer treatment. It also offers contract research services. The company has partnerships with Merck & Co., Inc.; Cancer Therapeutics Cooperative Research Centre; Genmab A/S; Laboratory Corporation of America (LabCorp); Athena Diagnostics; and Genetic Technologies Limited. Bionomics Limited was founded in 1998 and is based in Thebarton, Australia.
|RAP Resapp Health||0.2||33.3||6,699,681||-0.11||BEARISH|
|ONE Oneview Healthcare||0.23||9.8||3,200||-0.05||BEARISH|
|EVT Event Hospitality And Entertainment||12.42||7.1||78,857||-10.71||BEARISH|
|AFL ASX 50||0.19||5.6||5,000||-1.7||BEARISH|
|AGI Ainsworth Game Technology||0.77||5.5||174,715||-2.06||BEARISH|
|QMS Qms Media||0.86||5.5||487,379||0||BEARISH|